Clinical Rheumatology

, Volume 29, Issue 5, pp 517–524 | Cite as

Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha

  • Renato De Stefano
  • Elena Frati
  • Fernando Nargi
  • Caterina Baldi
  • Luana Menza
  • Mohammed Hammoud
  • Mauro Galeazzi
Original Article

Abstract

To compare the efficacy and safety of leflunomide (LEF)-anti-TNF-alpha combination therapy to methotrexate (MTX)-anti-TNF-alpha combination therapy in a group of patients with active rheumatoid arthritis (RA). We have recruited 120 patients with RA with a high disease activity despite being treated with MTX (15 mg/week) or LEF (20 mg/die) for 3 months, without side effects. In each of these patients, therapy with either MTX or LEF was continued and randomly combined with an anti-TNF-alpha drug: etanercept, infliximab, or adalimumab. Patients were assessed at study entry and at 4, 12, and at 24 weeks. The efficacy endpoints included variations in the DAS28-ESR and the ACR20, ACR50, and ACR70 responses. At each visit, any side-effect was recorded. There were no statistically significant differences in the DAS28 variations and in the ACR responses between the two groups or among the six subgroups. The number of discontinuation due to the appearance of serious side effects was higher, but not statistically significant, in the LEF-anti-TNF-alpha group than in the MTX-anti-TNF-alpha group. Other adverse events that did not necessitate the discontinuation of therapy occurred much more frequently in patients treated with MTX than in those treated with LEF. Anti-TNF-alpha drugs can be used in combination not only with MTX, but also with LEF, with the same probability of achieving significant clinical improvement in RA patients and without a significantly greater risk of serious adverse events. In contrast, it seems that combination therapy with LEF-anti-TNF-alpha is more readily tolerated than combination therapy with MTX-anti-TNF-alpha.

Keywords

Combination terapy DMARDs Rheumatoid arthritis TNFalpha blocking agents 

References

  1. 1.
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Mcfarlane JD et al (1998) Therapeutic efficacy of multiple intravenous infusion of anti-tumor necrosis factor alpha monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Atrhritis Rheum 41:1552–1563CrossRefGoogle Scholar
  2. 2.
    Lipsky PE et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343:1594–1602CrossRefPubMedGoogle Scholar
  3. 3.
    Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46:1443–1450CrossRefPubMedGoogle Scholar
  4. 4.
    Klareskog L, van der Heijde D, de Jager JP, Kalden J, Malaise M, Gough A et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised trial. Lancet 363:675–681CrossRefPubMedGoogle Scholar
  5. 5.
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT (2006) The PREMIER study: a multicenter, randomized, doble-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54(1):26–37CrossRefPubMedGoogle Scholar
  6. 6.
    Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35–45CrossRefPubMedGoogle Scholar
  7. 7.
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: result of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30(12):2563–2571PubMedGoogle Scholar
  8. 8.
    Nordström DC, Konttinen L, Korpela M, Tiippana-Kinnunen T, Eklund K, Forsberg S, Ilva K, Kaipiainen-Seppänen O, Malmi T, Ylä-Kerttula T, Honkanen V (2006) Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. Rheumatol Int 26:741–748CrossRefPubMedGoogle Scholar
  9. 9.
    Zink A, Listing J, Kary S et al (2005) Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 64:1274–1279CrossRefPubMedGoogle Scholar
  10. 10.
    O’Dell JR, Petersen K, Leff R, Palmer W, Schned E, Blakely K, Haire C, Fernandez A (2006) Etanercept in combination with Sulfasalazine, Hydroxychloroquine, or Gold in the treatment of rheumatoid arthritis. J Rheumatol 33:213–218PubMedGoogle Scholar
  11. 11.
    Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK et al (2006) Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis 65:1357–1362CrossRefPubMedGoogle Scholar
  12. 12.
    Burmester GR, Mariette X, Montecucco C, Monteagudo-Saez I, Malaise M, Tzioufas AG et al (2007) Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 66:732–739CrossRefPubMedGoogle Scholar
  13. 13.
    Patel SR, Bergen W, Kraemer A, Keenan G (2001) Efficacy and safety of remicade (infliximab) plus Arava (leflunomide) in rheumatoid arthritis. Arthritis Rheum 44(Suppl 9):S84Google Scholar
  14. 14.
    Kiely PDW, Johnson DM (2002) Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology 41:631–637CrossRefPubMedGoogle Scholar
  15. 15.
    Struppler C, Thies W, Schattenkirchner M, Kellner H (2002) Safety and efficacy of leflunomide and infliximab in rheumatoid arthritis patients. Ann Rheum Dis 61:S388Google Scholar
  16. 16.
    Godinho F, Godfrin B, El Mahou S, Navaux F, Zabraniecki L, Cantagrel A (2004) Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin Exp Rheumatology 22:328–330Google Scholar
  17. 17.
    Hansen KE, Cush J, Singhal A, Cooley DA, Cohen S, Patel SR, Genovese M, Sundaramurthy S, Schiff M (2004) The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum 51:228–232CrossRefPubMedGoogle Scholar
  18. 18.
    Ortiz Garcia AM, Gonzales-Alvaro I, Rosello Pardo R, Carmona L, Fabregas Canales MD, Monteagudo Saez I (2004) Effectiveness and safety of infliximab combined with leflunomide in chronic polyarthritis. Clin Exp Rheumatol 22:790PubMedGoogle Scholar
  19. 19.
    Bingham SJ, Buch MH, Kerr MA et al (2004) Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. Arthritis Rheum 50(12):4072–4073CrossRefPubMedGoogle Scholar
  20. 20.
    Flendrie M, Creemers MC, Welsing PM, van Riel PL (2005) The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology 44(4):472–478CrossRefPubMedGoogle Scholar
  21. 21.
    Kalden JR, Antoni C, Alvaro-Garcia JM, Combe B, Emery P, Kremer JM, Strand CV, Van Riel P, Smolen JS (2005) Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. J Rheumatol 32(8):1620–1631PubMedGoogle Scholar
  22. 22.
    Cobo Ibanez T, Yehia Tayel M, Balsa Criado A, Hernandez Sanz A, Martin Mola E (2005) Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis. Rheumatology 44:1467–1468CrossRefPubMedGoogle Scholar
  23. 23.
    Perdriger A, Mariette X, Kuntz JL, Brocq O, Kara-Terki R, Loet XL, Cantagrel A, Pavy S, Deslandre CJ, Debiais F, Combe B (2006) Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice. J Rheumatol 33(5):865–869PubMedGoogle Scholar
  24. 24.
    Wislowska M, Jacubicz D (2007) Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone. Rheumatol Int 27(7):641–647CrossRefPubMedGoogle Scholar
  25. 25.
    Kalden JR, Nuslein HG, Wollenhaupt J, Burmester GR, Kruger K, Antoni C (2008) Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in open-label clinical trial. Clin Exp Rheumatol 26:834–840PubMedGoogle Scholar
  26. 26.
    Finckh A, Dehler S, Gabay C, on behalf of the SCQM doctors (2009) The effectiveness of leflunomide as a co-therapy of tumor necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheu Dis 68:33–39CrossRefGoogle Scholar
  27. 27.
    Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, Listing J, Zink A (2009) Ann Rheu Dis 68:33–3Google Scholar
  28. 28.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–334CrossRefPubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2010

Authors and Affiliations

  • Renato De Stefano
    • 1
  • Elena Frati
    • 1
  • Fernando Nargi
    • 1
  • Caterina Baldi
    • 1
  • Luana Menza
    • 1
  • Mohammed Hammoud
    • 1
  • Mauro Galeazzi
    • 1
  1. 1.Rheumatology UnitAzienda Ospedaliera Universitaria SeneseSienaItaly

Personalised recommendations